Claims
- 1. A method of treating cancer, comprising delivering via inhalation a cancer treating effective amount of a stable platinum-containing formulation to the respiratory tract of an individual in need of such treatment; wherein the stable platinum-containing formulation comprises:(a) a milled, powder blend of cisplatin and sodium chloride, or cisplatin entrapped in sodium chloride crystals; and (b) one or more phospholipids.
- 2. A method of preparing a stable cisplatin-containing formulation suitable for administration by inhalation, comprising:(a) dissolving cisplatin in a supersaturated solution of sodium chloride; and (b) removing the water from the resulting solution of (a) to produce dry sodium chloride crystals which entrap the cisplatin to form the stable cisplatin-containing composition.
- 3. The method of claim 2, wherein the water is removed from the solution of (b) by evaporation, freeze drying, or spray drying.
- 4. The method of claim 2, wherein the resulting dry crystals of (b) are milled to a size appropriate for administration by inhalation.
- 5. The method of claim 2, wherein the water is removed from the solution of (b) under conditions that precipitate crystals of a size appropriate for administration by inhalation.
- 6. The method of claim 1, wherein the stable platinum-containing formulation is produced by:(a) milling dry cisplatin to a powder; (b) mixing the resulting cisplatin powder of (a) with sodium chloride as a dry powder blend, resulting in the milled, powder blend; and (c) combining the milled, powder blend with one or more phospholipids to form the stable platinum-containing formulation suitable for administration by inhalation.
- 7. The method of claim 1, wherein the stable platinum-containing formulation comprises liposomes.
- 8. The method of claim 7, wherein the liposomes have an average diameter of approximately 15 to 1000 nm.
- 9. The method of claim 8, wherein the liposomes have an average diameter of approximately 25 to 100 nm.
- 10. The method of claim 7, wherein the liposomes have an average diameter of greater than 1 micron.
- 11. The method of claim 10, wherein the liposomes have an average diameter of 2 to 5 microns.
- 12. The method of claim 1, wherein the stable platinum-containing formulation comprises one or more polymers.
- 13. The method of claim 1, wherein the stable platinum-containing formulation further comprises one or more polymers.
- 14. The method of claim 1, wherein the stable platinum-containing formulation comprises a carrier.
- 15. The method of claim 14, wherein the carrier comprises one or more hydrofluorocarbons or fluorochlorocarbons.
- 16. The method of claim 15, wherein the carrier comprises one or more of: 1,1,1,2,3,3,3-heptafluoropropane, 1,1,1,2-tetrafluoroethane, dichlorodifluoromethane, trichlorofluoromethane, or 1,2-dichloro-1,1,2,2-tetrafluoroethane.
- 17. The method of claim 1, wherein the stable platinum-containing formulation is a powder.
- 18. The method of claim 17, wherein the powder is delivered to the individual's respiratory tract as an aerosol.
- 19. The method of claim 17, wherein the formulation comprises one or more excipients.
- 20. The method of claim 19, wherein the excipient comprises one or more sugars.
- 21. The method of claim 17, wherein the stable platinum-containing formulation is delivered to the individual's lungs by a nebulizer.
- 22. The method of claim 1, wherein the stable platinum-containing formulation comprises a liquid.
- 23. The method of claim 22, wherein the liquid includes ethanol.
- 24. The method of claim 22, wherein the liquid is delivered to the individual's respiratory tract as an aerosol.
- 25. The method of claim 22, wherein the liquid is delivered to the individul's respiratory tract as a spray.
- 26. The method of claim 1, wherein the cancer is a cancer that originates in the lung.
- 27. The method of claim 26, wherein the cancer is small cell lung cancer.
- 28. The method of claim 26, wherein the cancer is non-small cell lung cancer.
- 29. The method of claim 1, wherein the cancer is a cancer that metastasized to the lung.
- 30. The method of claim 1, wherein the cancer is a cancer that metastasized to the lung lymphatics.
- 31. The method of claim 1, wherein the cancer is a cancer that originated in the liver or spleen.
- 32. The method of claim 1, wherein the cancer is a cancer that is in the liver or spleen.
- 33. The method of claim 1, wherein the cancer is a cancer that is in the bronchus, esophagus, or trachea.
- 34. The method of claim 1, wherein the cancer is a cancer that is metastasized in the bronchus, esophagus, or trachea.
- 35. The method of claim 1, wherein the cancer is leukemia.
- 36. The method of claim 1, wherein the cancer is a myeloma.
- 37. The method of claim 1, wherein the cancer is mesothelioma.
- 38. The method of claim 23, wherein the stable platinum-containing formulation comprises up to 2% by weight ethanol.
Parent Case Info
This Application claims benefit to a provisional application No. 60/313,528 filed on Aug. 20, 2001.
US Referenced Citations (10)
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/313528 |
Aug 2001 |
US |